Amgen and NovoCure are both positioned within healthcare, but they offer investors sharply different profiles for 2026: one is a cash-generating biopharmaceutical with broad commercial reach, while the other is a niche oncology device company that relies on a direct-to-patient approach. The decision between the two often comes down to whether investors prioritize established free-cash-flow durability or the potential for upside tied to clinical expansion and reimbursement momentum.
Amgen, a large-scale drugmaker focused on chronic disease and oncology, reported strong financial results for fiscal 2025, including substantial net income and positive free cash flow. NovoCure, known for tumor-treating electrical field therapy delivered via wearable technology, posted lower revenue and a net loss in fiscal 2025, with free cash flow remaining negative—underscoring a business still investing for growth and access.
Key takeaways
- Cash flow vs. funding needs: Amgen generated about $8.1 billion in free cash flow in fiscal 2025, while NovoCure reported negative $75.7 million in free cash flow.
- Catalyst for investors: Amgen’s results reflect scale and established franchises, while NovoCure’s trajectory hinges on regulatory approvals, payer coverage, and continued treatment adoption.
- Risk implication: Amgen faces policy and operational concentration risks; NovoCure faces execution and financing pressure tied to profitability timing.
- Valuation context: Amgen trades on positive earnings power, while the article notes NovoCure carries lower sales and forward earnings multiples than Amgen.
What drove the divergence in financial profiles
Amgen’s model is built around blockbuster medicines and a portfolio designed for long-term demand in conditions such as heart disease, obesity, and cancer. According to the article, Amgen’s revenue in fiscal 2025 reached nearly $36.8 billion, up roughly 10.1% year over year, and net income totaled $7.7 billion. The company also generated free cash flow of about $8.1 billion in fiscal 2025, supporting its ability to fund operations and strategic priorities internally.
NovoCure operates differently. The company sells its tumor-treating electrical field therapy using a direct-to-patient framework, collecting monthly device fees for treatment tools such as Optune Gio. The article frames this as a structure that can strengthen relationships with patients while reducing reliance on traditional wholesale distribution. For fiscal 2025, NovoCure reported revenue of approximately $655.4 million (about 8.3% growth), but also recorded a net loss of nearly $136.2 million. Free cash flow was negative at about $75.7 million, indicating the business has not yet converted growth into cash generation.
Market reaction: how investors may interpret the business models
While the article does not report specific share-price moves on a particular date, it highlights a fundamental market interpretation that typically shapes trading and investor positioning. For Amgen, positive free cash flow and large net income are key inputs that tend to support valuation and resilience, particularly when investors expect continued demand for established therapies. The scale also provides flexibility for capital allocation, including reinvestment and potential acquisitions, which can influence longer-term expectations for revenue growth.
For NovoCure, investors usually focus on whether revenue growth can translate into operating leverage and, eventually, free-cash-flow generation. The article notes that Wall Street is not anticipating free cash flow until fiscal 2028, which can place pressure on the company to finance ongoing operations in the interim. In device and specialty oncology categories, that funding need can also affect sentiment around dilution risk and the pace of market expansion.
Key risks investors are weighing
Amgen risk factors highlighted in the article include government pricing pressures associated with the Inflation Reduction Act, which mandates price-setting for certain drugs. The company also faces uncertainty from tax disputes with the IRS and a $20.2 million judgment against a subsidiary. In addition, the article points to manufacturing concentration, including locations such as Puerto Rico, which can increase exposure to natural disasters or infrastructure disruptions.
NovoCure risk factors center on dependency on regulatory approvals and compliance requirements tied to new indications and international medical standards. The article also emphasizes payer reimbursement dynamics: if claims are denied by payers such as Medicare, NovoCure may be forced to absorb costs. Competition is another concern, particularly from companies developing alternative technologies, as well as the eventual expiration of its patents through 2041.
Bigger picture: valuation and what it signals for 2026
The article asserts that NovoCure trades at lower multiples relative to its sales and future earnings estimates than Amgen, reflecting differing profitability levels and cash-flow timelines. It also notes that forward price-to-earnings and price-to-sales comparisons can differ by data provider, but uses Financial Modeling Prep metrics for context. Specifically, it lists Amgen’s forward P/E at 15.2x and P/S at 4.9x, while describing NovoCure’s forward P/E as not applicable within the table and giving its P/S at 2.6x. The sector benchmark referenced in the article is based on the SPDR XLV sector ETF.
For 2026 specifically, the article suggests Amgen could work out a roughly 3% revenue rise to about $37.8 billion, supported by its existing franchises. NovoCure is described as projecting revenue of about $704 million for 2026, but with less emphasis on near-term cash generation given the company’s expected free-cash-flow timing later in the decade.
What to watch next
Investors evaluating these names for 2026 should track Amgen’s ability to sustain cash generation amid ongoing policy and tax uncertainty, including any developments related to regulatory pricing and disputes highlighted in the article. For NovoCure, the key watch items are reimbursement stability and the cadence of regulatory milestones—particularly as the company expands clinical indications and works toward improving cash-flow timing. Upcoming catalysts typically include company-specific earnings updates and major healthcare policy or reimbursement decisions that can change expected demand and profitability trajectories.
